louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05202041: Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS
Official title: Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Non ST Segment Elevation Acute Coronary Syndrome
Coronary Artery Disease
Percutaneous Coronary Intervention
Lead sponsor: Wuhan Asia Heart Hospital
Sponsor class: OTHER
First posted: 2022-01-21
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.


Eligibility criteria: Inclusion Criteria:

* 18 Years and older
* Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
* Diameter stenosis of 50%-90% by visual estimate
* Reference vessel size \> 2 mm in stenotic segment by visual estimate

Exclusion Criteria:

* LVEF ≤ 40%
* eGFR \< 60 mL/min
* Allergy to contrast media, adenosine
* Prior CABG

Primary outcomes:
measure: Vessel-oriented composite endpoints (VOCEs)
timeFrame: 1 year
measure: Post-PCI AccuFFRangio
timeFrame: 1 year
Secondary outcomes:
measure: Cost analysis
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Wuhan Aisa Heart Hospital
name: Dan Song, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04605341: Miniplate Versus k Wires in Management of Metacarpal Fracture
Official title: Comparative Study Between Miniplate and Buried k Wires in Management of Metacarpal Fractures
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Metacarpal Fracture
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-10-28
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare between buried k wires and miniplate in management of metacarpal fracture.

Detailed description: Fractures of the carpals, metacarpals and phalanges account for approximately 15-19% of fractures in adults, with 59% of these occurring in the phalanges, 33% in the metacarpals and 8% in the carpal bones \[1\]. The single most common fracture site in the hand is the sub capital region of the fifth metacarpal bone (boxer's fracture) \[2\], which usually results from a direct blow to the metacarpal head \[3\]. Most hand fractures are caused by accidental falls or other sports-related injuries \[4\]. Hand fractures are among the most common fractures of upper extremity \[5, 6\]. Hand fractures can be treated conservatively or surgically, depending on the severity, location and type of fracture. The main objective of both operative and non-operative treatments is to provide fracture stability for early mobilization \[7\]. Surgical fixation is mainly indicated for displaced fractures because casts are often not sufficient to maintain reduction \[8\]. Open reduction with internal fixation (ORIF), using pins or plates, has historically been used to stabilize hand fractures which have rotational deformity or lateral angulation \[9\]. Open reduction may result in scarring, joint stiffness and tendon adhesion \[7\]. Closed reduction with internal fixation (CRIF), using percutaneous K wire or screws, is now used to treat the majority of unstable closed simple hand fractures \[10\]. It is generally considered percutaneous Kirschner wire (K wire) fixation may not provide adequate stabilization to allow for early mobilization \[8\] .

Eligibility criteria: Inclusion Criteria:

1. Age: ( 20-60) years,
2. Fresh (fixed within 3 days),
3. Single or multiple fractures of metacarpals.

Exclusion Criteria:

1. Pathological fracture,
2. Major systemic illness, malignancy,
3. Patient on drugs affecting fracture healing like steroid, anticancer drugs,
4. Polytrauma patients,
5. Extensive comminution of the metacarpal or phalanx detected pre- or intra-operatively,
6. Dislocations at either end of the fractured bone
7. Parents/guardians/patients not willing to participate in study.

Primary outcomes:
measure: miniplate,buried k wires and union
timeFrame: 6 month
Secondary outcomes:
measure: Range of motion
timeFrame: 6 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05772741: Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs
Official title: Grafts of Patient-derived Glioblastoma Stem Cells Onto Autologous Brain Organoids. A Precision Medicine Model for Testing Drugs Against Tumor Invasion
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glioblastoma
Glioma, Malignant
Keywords: glioma stem-like cells
brain organoids
brain invasion
ciliogenesis
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
Collaborators: name: Catholic University of the Sacred Heart
name: Istituto Superiore di Sanità
name: Heinrich-Heine University, Duesseldorf
First posted: 2023-03-16
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: In patients operated for glioblastoma, glioma stem-like cell lines will be obtained from tumor tissue, and IPSCs from skin fibroblasts or PBMCs. Brain organoids will be generated from IPSCs and co-cultured with IPSCs to study brain invasion and ciliogenesis. 3D genome architecture of glioma stem-like cells will be investigated. Gene modulation and pharmacologic strategies to inhibit invasion and restore ciliogenesis will be explored.


Eligibility criteria: Inclusion Criteria:

o be enrolled in the study patients must:

1. Have a radiological diagnosis of supratentorial glioblastoma, or
2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had made at first surgery), according with RANO criteria (Wen, 2010);
3. Be a candidate to neurosurgery for glioblastoma;
4. Be of an age of 18 years or above;
5. Provide written informed consent for participation to the study.

Exclusion criteria

To be enrolled in the study patients must not:

1. Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis and for the present study, as judged by the Principal Investigator;
2. Have not a definitive pathological diagnosis of a primary supratentorial glioblastoma, according with 2016 WHO classification.

Primary outcomes:
measure: Invasion
timeFrame: through study completion, an average of 4 years
measure: Gene assessment
timeFrame: through study completion, an average of 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Fondazione Policlinico Universitario A. Gemelli IRCCS
Study officials:
References:
Clinical trial NCT00116441: Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
Official title: Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
Cancer
PSCT
Peripheral Stem Cell Transplant
Chemotherapy
GVAX
Lead sponsor: Cell Genesys
Sponsor class: INDUSTRY
First posted: 2005-06-30
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.


Eligibility criteria: Inclusion Criteria:

* De novo multiple myeloma
* ECOG 0-2
* No serious co-morbid illnesses and adequate organ function
* \> 4 weeks from systemic steroids

Exclusion Criteria:

* No existing secondary malignancies and no history of secondary malignancies in the past 5 years
* No active autoimmune disease

Primary outcomes:
measure: Multiple myeloma
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
References:
Clinical trial NCT04880941: Progressive Relaxation Exercise Applied to Palliative Caregivers on Coping With Stress,Anxiety
Official title: The Effect of Progressive Relaxation Exercise Applied to Palliative Caregivers on Coping With Stress and Anxiety Variables
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palliative Care
Keywords: Progressive Relaxation Exercise
Coping With Stress
Anxiety
Lead sponsor: Istanbul Sabahattin Zaim University
Sponsor class: OTHER
First posted: 2021-05-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is an experimental study with pre-test and post-test control groups.
Primary purpose: SUPPORTIVE_CARE

Brief summary: It is important to consider the needs of palliative care caregivers and to plan interventions for psychosocial problems.

Detailed description: Cognitive-behavioral methods, which may be applied as relaxation aids in controlling the anxiety levels.

Eligibility criteria: Inclusion Criteria:

* To be able to communicate adequately
* Not having psychiatric problems
* Volunteering to participate in research
* Caregivers whose patients will be in bed for at least 4 weeks

Exclusion Criteria:

* None

Primary outcomes:
measure: Coping With Stress in Palliative Caregivers
timeFrame: 1 week
measure: Coping With Stress in Palliative Caregivers
timeFrame: 4 week
Secondary outcomes:
measure: Anxiety in Palliative Caregivers
timeFrame: 1 week
measure: Anxiety in Palliative Caregivers
timeFrame: 4 week
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Sabahattin Zain Universitiy
state: State
Study officials:
affiliation: Istanbul Sabahattin Zaim University
name: Zülfünaz ÖZER, PhD
role: STUDY_CHAIR
References:
citation: Tsitsi T, Charalambous A, Papastavrou E, Raftopoulos V. Effectiveness of a relaxation intervention (progressive muscle relaxation and guided imagery techniques) to reduce anxiety and improve mood of parents of hospitalized children with malignancies: A randomized controlled trial in Republic of Cyprus and Greece. Eur J Oncol Nurs. 2017 Feb;26:9-18. doi: 10.1016/j.ejon.2016.10.007. Epub 2016 Nov 18.
citation: Borji M, Nourmohammadi H, Otaghi M, Salimi AH, Tarjoman A. Positive Effects of Cognitive Behavioral Therapy on Depression, Anxiety and Stress of Family Caregivers of Patients with Prostate Cancer: A Randomized Clinical Trial. Asian Pac J Cancer Prev. 2017 Dec 28;18(12):3207-3212. doi: 10.22034/APJCP.2017.18.12.3207.
Clinical trial NCT01407341: Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer
Official title: ChronOS Stability Study: For Metastatic Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Adult Spinal Cord Neoplasm
Spinal Bone Metastases
Spinal Cord Compression
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-08-02
Enrollment: 1
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This pilot clinical trial studies beta-tricalcium phosphate bone graft in treating patients undergoing surgery for metastatic spine cancer. A bone graft may help healing and bone growth in patients undergoing surgery for spine cancer

Detailed description: OBJECTIVES: I. To determine if Chronos (beta-tricalcium phosphate bone graft) will form a posterolateral fusion mass in patients undergoing fusion surgery for spine cancer within 12 months. II. To evaluate quality of life following the use of ChronOS as measured by (a) pain (or lack of pain) associated with pseudoarthrosis and (b) the need for additional treatment for instability as a result of hardware failure. OUTLINE: Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery. After completion of study treatment, patients are followed up at 1 month and then every 3 months for 1 year.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing surgery for spinal decompression for tatic spine cancer who require bone substitute for a posterolateral spinal fusion
* Patients may or may not have posterolateral instrumentation

Exclusion Criteria:

* Status-post previous fusion with allogeneic bone graft

Primary outcomes:
measure: Achievement of durable posterolateral fusion
timeFrame: Within 12 months
Secondary outcomes:
measure: Achievement of posterolateral fusion
timeFrame: Up to 12 months
measure: Occurrence of subsequent hardware failure
timeFrame: Every 3 months for 12 months
measure: Requirement of additional treatment is for instability
timeFrame: Within 12 months
measure: First documentation of posterolateral fusion
timeFrame: Within 12 months
measure: Occurrence of pain or disability experienced after surgery that is related to spinal metastasis or is a consequence of the resulting treatment
timeFrame: Every 3 months for 12 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: Thomas Chen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06876519: Clinical Efficacy of Different Maxillary Sinus Floor Elevation Procedures
Official title: Clinical Efficacy of Different Maxillary Sinus Floor Elevation Procedures Based on Maxillary Sinus Anatomy
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Maxillary Sinus Floor Elevation
Lead sponsor: Hospital of Stomatology, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2025-03-14
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region, and having successful osseointegration after 6 months from surgery.

Brief summary: The goal of this study is to investigate the clinical efficacy of different maxillary sinus floor elevation procedures based on maxillary sinus anatomy.

The main questions it aims to answer are:

* How does the anatomical morphology of maxillary sinus affect postoperative bone resorption?
* How to select the appropriate maxillary sinus floor elevation procedure based on maxillary sinus anatomy? Preoperative, immediate postoperative, and six-month postoperative CBCT images of patients undergoing translateral maxillary sinus floor elevation or hydraulic transcrestal maxillary sinus floor elevation will be measured.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing translateral maxillary sinus floor elevation or hydraulic transcrestal maxillary sinus floor elevation in the maxillary molar region.
* Patients undergoing maxillary sinus floor elevationwith simultaneous implantation in the maxillary molar region，and having successful osseointegration after 6 months from surgery.
* Patients having CBCT examination for preoperative, the day of surgery, and six months after surgery.
* Patients treated between January 1, 2016 and June 30, 2024.

Exclusion Criteria:

* Patients having osteointegration failure within six months after surgery.
* Refusal to participate in the study.
* Other conditions deemed unsuitable for participation by the investigator.

Primary outcomes:
measure: Bone loss
timeFrame: 6 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital of Stomatology, Sun Yat-Sen University
name: Jinming Wang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02230319: Prevention of Paclitaxel Neuropathy With Cryotherapy
Official title: Prevention of Paclitaxel Neuropathy With Cryotherapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Cryotherapy
Cold therapy
Peripheral Neuropathy
Paclitaxel
Breast Cancer
Symptom management
Prevention
Lead sponsor: Medical Oncology & Hematology Associates of Northern Virginia
Sponsor class: OTHER
Collaborators: name: Inova Health Care Services
First posted: 2014-09-03
Enrollment: 39
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine if cryotherapy can effectively decrease the rate of neuropathy in patients undergoing weekly paclitaxel treatments.


Eligibility criteria: Inclusion Criteria

1. Women 18 years of age or older
2. Histologically or cytological proven diagnosis of breast cancer Stage I- III.
3. Must pl an to receive weekly paclitaxel treatment in either the adjuvant or neoadjuvant setting.
4. May have received prior treatment including, radiation, surgery chemotherapy hormone and biologics.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
6. Patient signed informed consent.
7. Patient willing and able to comply with scheduled visits and treatment plan.

Exclusion Criteria

1. Patient presents with Grade 2 or greater peripheral neuropathy.
2. History of Raynaud's Disease.
3. Patient presents open or poorly-healing wounds on the hands or feet.
4. Patients with cold intolerance.
5. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation.

Primary outcomes:
measure: Incidence of grade 2 peripheral neuropathies induced by weekly paclitaxel.
timeFrame: From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
Secondary outcomes:
measure: Rate of completion of weekly adjuvant paclitaxel with the use of cryotherapy.
timeFrame: From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
Other outcomes:
Locations:
city: Fairfax
country: United States
facility: Medical Oncology & Hematology Associates of Northern Virginia
state: Virginia
city: Reston
country: United States
facility: Medical Oncology & Hematology Associates of Northern Virginia
state: Virginia
Study officials:
affiliation: Medical Oncology & Hematology Associates of Northern Virginia
name: Mary J Wilkinson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06668519: Magnetoencephalography in Children
Official title: An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Epilepsy
Intracranial Tumors
Cerebrovascular Disease
Autism
ADHD - Attention Deficit Disorder With Hyperactivity
Neuropsychiatric Disorders
Tic Disorder, Childhood
Mental Retardation
Developmental Disabilities
Keywords: neurodevelopmental diseases
magnetoencephalography
pediatric
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 1500
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children aged 1 month to 18 years old

Brief summary: This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.

Detailed description: The purpose of this study is to observe the application of magnetoencephalography (MEG) in pediatric neurodevelopmental disorders

Eligibility criteria: Inclusion Criteria:

1. aged 1 month-18 years old (date of investigate minus date of birth)
2. epilepsy
3. intracranial tumors
4. cerebrovascular diseases
5. autism
6. mental retardation
7. ADHD
8. tic disorder
9. neuropsychiatric disorders

Exclusion Criteria:

1.Unable to cooperate with the exam of MEG

Primary outcomes:
measure: Difference in magnetoencephalography (MEG) signal between children with neurodevelopmental diseases and healthy children
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's Hospital of Fudan University
Study officials:
References:
Clinical trial NCT01269619: Comparative Study of Static and Dynamic Back Supports for Lower Back Pain
Official title: Comparative Study of Static and Dynamic Back Supports for Lower Back Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain, Mechanical
Keywords: back pain
posture
lumbar support
dynamic support
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-01-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Lower back pain is one of the most common conditions affecting humans. Lower back supports are a common device used in order to alleviate the pain. All the available back supports are wrapped around the lower back and abdomen and act as static support devices. "The hug" is a new dynamic back support where the participant actively improves his/her posture and strengthens the muscle of the lower back. This trial compares both devices and their effect on reducing lower back pain.


Eligibility criteria: Inclusion Criteria:

* Recurrent back pain
* use analgesics

Exclusion Criteria:

* Pregnant women
* malignancy
* infection
* neurological condition
* surgical candidate

Primary outcomes:
measure: Reduction in back pain
timeFrame: 3 weeks
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Holon
country: Israel
facility: Wolfson Medical Center
Study officials:
References: